Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. 2015

Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

BACKGROUND Higher angiotensin-converting enzyme (ACE) activity might increase the risk of Alzheimer's disease by increasing blood pressure, and subsequent development of cerebral small vessel disease (CSVD). Yet, it may also decrease this risk, as it functions to degrade amyloid-β, thereby reducing brain atrophy. OBJECTIVE To examine the cross-sectional associations of serum and cerebrospinal fluid (CSF) ACE protein levels and activity with brain atrophy and CSVD in a memory clinic cohort. METHODS In 118 subjects from the memory clinic based Amsterdam Dementia Cohort (mean age 66 ± 8 years), ACE protein levels (ng/ml) and activity in CSF and serum were investigated. Poisson regression analyses were used to associate ACE measurements with rated global cortical atrophy, medial temporal lobe atrophy, lacunar infarcts, white matter hyperintensities, and microbleeds on brain MRI. RESULTS Higher CSF ACE activity was associated with a reduced risk of global brain atrophy. The relative risk (95% CI) of having global cortical atrophy ≥2 per SD increase in CSF ACE activity was 0.67 (0.49; 0.93). ACE levels were not significantly related to measures of CSVD. CONCLUSIONS These results show that high ACE might have protective effects on the brain. This could suggest that ACE inhibitors, which may lower CSF ACE levels, are not preferred as antihypertensive treatment in patients at risk for Alzheimer's disease.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
March 1992, Clinical chemistry,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
January 2005, Annales de biologie clinique,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
August 1985, Neurology,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
January 1988, Brain research,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
August 2015, Journal of neuroimmunology,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
March 1991, Biochemistry international,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
October 1991, Scottish medical journal,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
January 1984, Enzyme,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
June 2003, Clinical chemistry,
Hadassa M Jochemsen, and Wiesje M van der Flier, and Emma L Ashby, and Charlotte E Teunissen, and Ruth E Jones, and Mike P Wattjes, and Philip Scheltens, and Mirjam I Geerlings, and Patrick G Kehoe, and Majon Muller
October 1987, Klinische Wochenschrift,
Copied contents to your clipboard!